Abstract Objective: Investigate miR-486-3p's role in alleviating age-related angiogenic decline in Moyamoya disease (MMD) by regulating senescent endothelial cells. Methods: Clinical analysis of 151 MMD patients correlated age with postoperative angiogenesis (DSA grading). Senescent HUVECs (SA-β-gal>80%) exhibited elevated SASP factors (IL-6/IL-8/MCP-1). Functional assays (EdU/Transwell/Matrigel) and bioinformatics identified miR-486-3p targets, validated via luciferase/Western blot.
